title: The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
abstract: Bispecific antibody (BsAb) has been proved to be a very effective antitumor approach because of its distinctive advantages of immune-mediated cytotoxicity. To enhance the ability to recruit and activate T lymphocytes for tumor-specific killing, we constructed and prepared a recombinant human single-chain Fv bispecific antibody (BsAb), named VEGFR1/CD3 BsAb, targeting VEGFR1 and CD3. The VEGFR1/CD3 BsAb was expressed in CHO-K1 cells and purified by Ni-NTA affinity chromatography. The CD3 and VEGFR1-binding activity of VEGFR1/CD3 BsAb was confirmed by flow cytometry. T lymphocyte activation and proliferation induced by VEGFR1/CD3 BsAb were also demonstrated in vitro. Notably, our VEGFR1/CD3 BsAb presented a powerful and specific killing effect against VEGFR1-positive human breast cancer cell MDA-MB-231 and MDA-MB-435 through activating T lymphocyte at very low concentrations, indicating that it will be a valuable antibody drug for treatment of VEGFR1-positive cancers in the future.
authors: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.|Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, People's Republic of China.
authors: Ping
authors: P
authors: Tang
authors: Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.
authors: Li
authors: L
authors: Li
authors: The Gastroenterology Tumor and Microenvironment Laboratory, Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, People's Republic of China.
authors: Yan
authors: Y
authors: Zhou
authors: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
authors: Cong-Cong
authors: CC
authors: Shen
authors: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
authors: Yu-Huan
authors: YH
authors: Kang
authors: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.|Guangdong Zhongsheng Pharmaceutical Company Limited, Dongguan, People's Republic of China.
authors: Yu-Qin
authors: YQ
authors: Yao
authors: Division of Abdominal Cancer, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
authors: Cheng
authors: C
authors: Yi
authors: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
authors: Lan-Tu
authors: LT
authors: Gou
authors: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.|Guangdong Zhongsheng Pharmaceutical Company Limited, Dongguan, People's Republic of China.
authors: Jin-Liang
authors: JL
authors: Yang
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis* / Q000276:immunology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D017252:CD3 Complex / Q000276:immunology*; D016466:CHO Cells; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003412:Cricetulus; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific; D017252:CD3 Complex; D040281:Vascular Endothelial Growth Factor Receptor-1
keywords: T lymphocyte; VEGFR1/CD3 BsAb; antibody drug; immunotherapy; tumor